Gamida Cell Ltd., a leader in the field of cell therapy, has just announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and accompanying warrants. These securities are being offered at a public offering price of $1.30 per ordinary share and accompanying warrant, for a total of approximately $22.8 million before underwriting discounts and commissions.
The warrants have an exercise price of $1.35 per share, are exercisable immediately, and will expire five years from the date of issuance. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 ordinary shares and/or warrants. The offering is expected to close on or about April 21, 2023, pending satisfaction of customary closing conditions.
With the proceeds from this offering, together with its current cash and trading financial assets, Gamida Cell will be able to drive the commercialization of its revolutionary drug, Omisirge®. It will also be able to further the clinical development of GDA-201, as well as cover general corporate expenses and working capital needs.
Piper Sandler & Co. has been chosen as the sole manager for this exciting offering, giving investors the opportunity to get involved in something truly special.
About Gamida Cell
Gamida Cell is revolutionizing the cell therapy industry, pioneering a powerful therapeutic approach that utilizes the properties of nicotinamide (NAM) to expand and enhance cells. The FDA-approved Omisirge® is an allogeneic hematopoietic progenitor cell therapy, while GDA-201, an intrinsic NK cell therapy candidate, is being investigated as a potential treatment for hematologic malignancies. By employing their innovative NAM technology, Gamida Cell is on a mission to bring curative treatments to patients suffering from these life-threatening ailments.